As part of the EU’s efforts to hasten the availability of a vaccine against the novel corinavirus, the European Parliament has adoped a regulation allowing such vaccines and treatments be developed more quickly.
Developing and deploying an effective and safe vaccine against the virus is the most likely permanent solution to stop the pandemic, said the MEPs in a statement after the vote which saw more than 500 lawmakers vote in favour.
To this end, the Commission has proposed an EU vaccines strategy for COVID-19 including a temporary and strictly COVID-19-related derogation from certain rules for clinical trials.
Clinical trials for COVID-19 vaccines are a time-consuming step before authorisation, as they need to be carried out in several member states to ensure the populations for whom the vaccines are intended are represented and to generate robust and conclusive data.
Some COVID-19 vaccines and treatments already being developed may be defined genetically modified organisms (GMOs) and are thus covered by the relevant EU GMO Directives. As national requirements to assess the environmental risks of clinical trials on medicinal products that contain or consist of GMOs vary considerably across member states, a derogation from these rules is needed to avoid significant delay in developing life-saving vaccines and treatments.
The derogation will facilitate the development, authorisation and consequently availability of COVID-19 vaccines and treatments. When debated last week in the Committee on the Environment, Public Health and Food Safety, members agreed on the need to adapt the rules but stressed that standards for vaccine quality, safety and efficacy must be maintained.